DS
AXDX

David Shaw’s Accelerate Diagnostics AXDX Stock Holding History

David Shaw’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,880
Closed -$619K – 3999
2014
Q3 		$619K Buy
2,880
+1,060
+58% +$206K ﹤0.01% 3181
2014
Q2 		$473K Buy
+1,820
New +$397K ﹤0.01% 3572

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

David Shaw's AXDX Position: Q2 2022 in Review

David Shaw sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 22,512 shares — an estimated $324K sold.

David Shaw first reported a position in AXDX in Q2 2014 and held it in 23 quarters. The position peaked at $1.51M in Q2 2020. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • David Shaw reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 22,512 Accelerate Diagnostics shares in Q2 2022, an estimated $324K.
  • David Shaw first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 23 quarters.
  • David Shaw's Accelerate Diagnostics position peaked at $1.51M in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.